Studies have shown that neoadjuvant nivolumab may provide long-term benefits for people with non-small cell lung cancer.

Published Date: 17 Feb 2023

BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.

2.

Renewing the call for a national Cancer Patient's Bill of Rights

3.

finding fresh approaches to treating diffuse midline gliomas.

4.

How the metastasis of cancer is driven by cellular plasticity.

5.

Women who miss their first mammogram face higher risk of breast cancer death, study finds


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot